Oragenics (NYSE:OGEN) Coverage Initiated by Analysts at StockNews.com

by · The Markets Daily

StockNews.com started coverage on shares of Oragenics (NYSE:OGEN – Free Report) in a research report released on Sunday. The brokerage issued a sell rating on the stock.

Oragenics Trading Down 1.7 %

Shares of NYSE OGEN opened at $0.31 on Friday. Oragenics has a 12-month low of $0.29 and a 12-month high of $7.74. The stock has a market cap of $1.41 million, a PE ratio of -0.04 and a beta of 0.45. The company has a 50-day moving average of $0.58 and a 200 day moving average of $1.11.

Oragenics (NYSE:OGEN – Get Free Report) last announced its quarterly earnings data on Friday, August 9th. The company reported ($0.51) earnings per share (EPS) for the quarter.

Institutional Trading of Oragenics

An institutional investor recently bought a new position in Oragenics stock. Virtu Financial LLC acquired a new position in shares of Oragenics, Inc. (NYSE:OGEN – Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned 0.51% of Oragenics as of its most recent filing with the SEC. Institutional investors own 18.71% of the company’s stock.

About Oragenics

(Get Free Report)

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.

Read More